Charles Witherspoon Sells 703 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) Stock

West Pharmaceutical Services, Inc. (NYSE:WST) VP Charles Witherspoon sold 703 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $310.40, for a total transaction of $218,211.20. Following the sale, the vice president now directly owns 1,253 shares of the company’s stock, valued at $388,931.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Charles Witherspoon also recently made the following trade(s):

• On Monday, August 19th, Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00.

West Pharmaceutical Services Price Performance

NYSE:WST opened at $316.50 on Friday. The stock has a 50 day moving average of $301.68 and a two-hundred day moving average of $319.76. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70. The firm has a market cap of $22.92 billion, a P/E ratio of 46.96, a price-to-earnings-growth ratio of 23.58 and a beta of 1.01. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, October 24th. The medical instruments supplier reported $1.85 EPS for the quarter, beating the consensus estimate of $1.50 by $0.35. The firm had revenue of $746.90 million during the quarter, compared to the consensus estimate of $709.62 million. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. The firm’s revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.16 EPS. On average, analysts expect that West Pharmaceutical Services, Inc. will post 6.69 earnings per share for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 20th. Stockholders of record on Wednesday, November 13th will be paid a $0.21 dividend. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.20. This represents a $0.84 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend is Wednesday, November 13th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.87%.

Institutional Trading of West Pharmaceutical Services

Large investors have recently bought and sold shares of the business. Fidelis Capital Partners LLC purchased a new position in West Pharmaceutical Services in the 1st quarter worth approximately $27,000. Northwest Investment Counselors LLC acquired a new stake in shares of West Pharmaceutical Services in the third quarter valued at approximately $30,000. Crewe Advisors LLC lifted its position in West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 71 shares in the last quarter. ORG Partners LLC boosted its stake in West Pharmaceutical Services by 820.0% during the first quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 123 shares during the last quarter. Finally, Quest Partners LLC grew its holdings in West Pharmaceutical Services by 5,633.3% in the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock valued at $57,000 after buying an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.